Esperion Therapeutics (ESPR) to Buy at Jefferies ahead of ACC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Morgan Stanley Opens Catalyst Driven Idea on Esperion Therapeutics (ESPR)
February 27, 2023 4:21 PM ESTMorgan Stanley analyst Jeffrey Hung reiterated an Equalweight rating and $9.00 price target on Esperion Therapeutics (NASDAQ: ESPR)
The analyst comments "What is the catalyst? Data from Esperion's CLEAR outcomes study for LDLlowering drug Nexletol (bempedoic acid) in 14,000+ statin intolerant patients at high risk for cardiovascular disease will be presented in a... More
Jefferies Assumes, Upgrades Esperion Therapeutics (ESPR) to Buy; Sees 100% Upside
February 24, 2023 6:49 AM EST(Updated - February 24, 2023 9:20 AM EST)
Jefferies analyst Dennis Ding assumes coverage on Esperion Therapeutics (NASDAQ: ESPR) and upgraded shares to Buy with a price target of $12 (from $6).
The analyst commented, "Assuming and UG to Buy on better mgmt tone... More
